IP Library Patent Application 14868615
Patent Application
App. No. 14/868,615

Treatment selection for lung cancer patients using mass spectrum of blood-based sample

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/868,615
Abstract

A test for predicting whether a non-small-cell lung cancer patient is more likely to benefit from an EGFR-I as compared to chemotherapy uses a computer-implemented classifier operating on a mass spectrum of a blood-based sample obtained from the patient. The classifier makes use of a training set which includes mass spectral data from blood-based samples of other cancer patients who are members of a class of patients predicted to have overall survival benefit on EGFRI-Is, e.g., those patients testing VS Good under the test described in U.S. Pat. No. 7,736,905. This class-labeled group is further subdivided into two subsets, i.e., those patients which exhibited early (class label “early”) and late (class label “late”) progression of disease after administration of the EGFR-I in treatment of cancer.

Claims (13)

1 . A method of generating a class label for a sample;

a) generating mass spectra of a development set of samples;

b) with the aid of a computer, generating a classifier from the mass spectra of the development set of samples;

c) obtaining a set of feature-dependent noise characteristics from the mass spectra of the development set of samples;

d) generating a mass spectrum of the sample;

e) generating a set of noisy feature value realizations of feature values of the mass-spectrum of the sample;

f) applying the classifier generated in step b) to the noisy feature value realizations and collating the results of the applying step;

g) generating statistical data on the results collated in step f); and

h) using the statistical data generated in step g) to determine a class label for the sample.

2 . The method of claim 1 , wherein the sample comprises a blood-based sample and wherein the development set of samples are in the form of a set of blood-based samples.

3 . The method of claim 1 , wherein the samples are obtained from a human with a disease.

4 . The method of claim 3 , wherein the disease is cancer.

5 . The method of claim 1 , wherein the noisy feature value realizations include both additive and multiplicative feature dependent noise characteristics.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
To: BIODESIX, INC.
Reel/Frame 055657/0911 →
SECURITY INTEREST Recorded Feb 23, 2018
From: BIODESIX, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 045022/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2015
From: RÖDER, HEINRICH; RÖDER, JOANNA
To: BIODESIX, INC.
Reel/Frame 036679/0897 →